10 November 2014
A new vaccine, which is commonly used to tackle tumour vessels, is effective at reducing the tumour itself and suppressing spontaneous lung metastases, a new study has found.
Published in the scientific journal Oncotarget, a team from Uppsala University demonstrated that a therapeutic vaccine could target a specific molecule key for tumour vasculature in adults. They found that the effect was significant, despite the aggressive nature of the tumour model.
The vaccine was able to reduce metastasis by 80 per cent, which could be important for future cancer therapy as most deaths are caused by the disease having spread throughout the body.
“The vaccination approach we have employed is not prophylactic but therapeutic, meaning that immunity was induced after the onset of tumorigenesis - a scenario that resembles the clinical conditions much more closely than prophylactic immunisation studies," said Anna-Karin Olsson, researcher at the Department of Medical Biochemistry and Microbiology at Uppsala University and leader of the study.
One of the advantages of the new approach is that the target molecule ED-A is present in the majority of solid tumours, meaning vaccinating against it could provide a treatment strategy for multiple forms of the disease.
Posted by Jeanette Royston
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.